Insulin– tag –
-
Novo Nordisk Partners with India’s Shantha Biologics for Global Cartridge Fill-Finish Services
The SouthFirst India Overview Novo Nordisk has signed an outsourcing agreement with Hyderabad-based Shantha Biologics for cartridge fill-finish manufacturing services for its global supply chain. This strategic collaboration signifies Sh... -
Dexcom Stelo Secures First FDA OTC CGM Approval, Abbott Advances Freestyle Libre 3 Plus with 15-Day Wear & AID Compatibility
CNET USA Overview Dexcom's Stelo achieved the first FDA approval for an over-the-counter Continuous Glucose Monitor (CGM) in 2024, significantly broadening access for general consumers. Concurrently, Abbott's Freestyle Libre 3 Plus enter... -
ALR Technologies to Acquire CGM Medical Shenzhen, Boosting CGM Manufacturing Capacity to 300,000 Units Monthly by January 2027
ALR Technologies (Press Release) USA Overview ALR Technologies announced plans to acquire CGM Medical Shenzhen to enhance its development of accurate and affordable continuous glucose monitor (CGM) devices for diabetes management. This a... -
DexCom Expands Stelo Glucose Biosensor to Non-Insulin-Using Children, Launches Redesigned App in US July 2026
WealthMagik (via Earnings Stability Report) USA Overview DexCom announced FDA approval to expand the Stelo Glucose Biosensor to non-insulin-using children aged 2 and older, aligning with the company's mission to make glucose sensing more... -
The Rise of Finger-Prick-Free Glucose Monitoring: Dexcom Stelo, Abbott Lingo, and the CGM Revolution in Metabolic Health
Mattioli 1885 イタリア Overview The U.S. FDA has approved a new generation of finger-prick-free continuous glucose monitors (CGMs) that measure interstitial fluid glucose and transmit real-time data to smartphones, largely eliminating da... -
FDA Clears Dexcom Stelo as First OTC Continuous Glucose Monitor for Non-Insulin-Using Children (Ages 2+)
HCPLive USA Overview The FDA has approved Dexcom's Stelo Glucose Biosensor System for over-the-counter (OTC) use in children aged 2 years and older who do not use insulin. This marks Stelo as the first OTC continuous glucose monitoring (... -
ADA 2026: CGM Applications Expand to Type 2 Diabetes; Continuous Ketone Monitoring and Dual Sensors Advance DKA Prevention
Pharmacy Times USA Overview The 86th American Diabetes Association (ADA) Scientific Sessions in 2026 highlighted a significant expansion of continuous glucose monitoring (CGM) beyond intensive insulin management to a broader Type 2 diabe... -
CNET Names Dexcom Stelo, Abbott FreeStyle Libre 3 Plus, and Eversense 365 as Top Continuous Glucose Monitors for 2026, Setting New Standards in Blood Sugar Management
CNET USA Overview CNET's 2026 review identifies Dexcom Stelo, Abbott FreeStyle Libre 3 Plus, and Eversense 365 as leading continuous glucose monitoring (CGM) devices. These systems excel in sensor life, accuracy, and FDA approval status,... -
Synthetic Biology Firm Syntax Bio Expands Series A to $14.4M, Boosting Preclinical Research for CRISPR-Based Type 1 Diabetes Beta-Cell Therapy
Fierce Biotech USA Overview Synthetic biology company Syntax Bio announced an expansion of its Series A funding round to $14.4 million, pushing total capital raised over $25 million. This capital injection will primarily drive the develo... -
2026 Digital Blood Sugar Meters: CGM Revolutionizes Metabolic Awareness with Real-Time Trends and Historical Data
[Unnamed Health Publication] Unknown Overview An analysis of digital blood sugar meters in 2026 highlights the distinction between traditional meters, which provide single readings, and Continuous Glucose Monitoring (CGM) devices that of...
